Results 1 to 10 of about 177 (68)

Review of the novel antifungal drug olorofim (F901318) [PDF]

BMC Infectious Diseases
There is clearly a need for novel antifungal agents, not only concerning spectrum, but also oral bioavailability, tolerability, and drug-drug interactions.
Yuri Vanbiervliet, Tine Van Nieuwenhuyse, Robina Aerts, Katrien Lagrou, Isabel Spriet, Johan Maertens   +5 more
doaj   +5 more sources

The Dynamic Influence of Olorofim (F901318) on the Cell Morphology and Organization of Living Cells of Aspergillus fumigatus [PDF]

Journal of Fungi, 2020
The first characterized antifungal in the orotomide class is olorofim. It targets the de novo pyrimidine biosynthesis pathway by inhibiting dihydroorotate dehydrogenase (DHODH).
Saskia du Pré, Mike Birch, Derek Law, Nicola Beckmann, Graham E. M. Sibley, Michael J. Bromley, Nick D. Read, Jason D. Oliver   +7 more
doaj   +6 more sources

Correction: Review of the novel antifungal drug olorofim (F901318) [PDF]

BMC Infectious Diseases
Yuri Vanbiervliet, Tine Van Nieuwenhuyse, Robina Aerts, Katrien Lagrou, Isabel Spriet, Johan Maertens   +5 more
doaj   +3 more sources

Resistance profiling of Aspergillus fumigatus to olorofim indicates absence of intrinsic resistance and unveils the molecular mechanisms of acquired olorofim resistance [PDF]

Emerging Microbes and Infections, 2022
Olorofim (F901318) is a new antifungal currently under clinical development that shows both in vitro and in vivo activity against a number of filamentous fungi including Aspergillus fumigatus. In this study we screened A. fumigatus isolates for intrinsic
Jochem B. Buil, Jason D. Oliver, Derek Law, Tim Baltussen, Jan Zoll, Margriet W.J. Hokken, Marlou Tehupeiory-Kooreman, Willem J.G. Melchers, Mike Birch, Paul E. Verweij   +9 more
doaj   +2 more sources

Antifungal Susceptibility Profiles of Olorofim (Formerly F901318) and Currently Available Systemic Antifungals against Mold and Yeast Phases of Talaromyces marneffei. [PDF]

Antimicrob Agents Chemother, 2021
In vitro antifungal susceptibility profiling of 32 clinical and environmental Talaromyces marneffei isolates recovered from southern China was performed against olorofim and 7 other systemic antifungals, including amphotericin B, 5-flucytosine, posaconazole, voriconazole, caspofungin, and terbinafine ...
Zhang J, Liu H, Xi L, Chang YC, Kwon-Chung KJ, Seyedmousavi S.   +5 more
europepmc   +4 more sources

Review of the Novel Investigational Antifungal Olorofim [PDF]

Journal of Fungi, 2020
The incidence of invasive fungal infections caused by molds and endemic fungi is increasing. There is also concern regarding increased rates of reduced susceptibility or frank resistance among Aspergillus and Coccidioides species, while Scedosporium ...
Nathan P. Wiederhold
doaj   +2 more sources

Effect of the Novel Antifungal Drug F901318 (Olorofim) on Growth and Viability of Aspergillus fumigatus. [PDF]

Antimicrob Agents Chemother, 2018
F901318 (olorofim) is a novel antifungal drug that is highly active against Aspergillus species. Belonging to a new class of antifungals called the orotomides, F901318 targets dihydroorotate dehydrogenase (DHODH) in the de novo pyrimidine biosynthesis pathway.
du Pré S, Beckmann N, Almeida MC, Sibley GEM, Law D, Brand AC, Birch M, Read ND, Oliver JD.   +8 more
europepmc   +5 more sources

Potency of olorofim (F901318) compared to contemporary antifungal agents against clinical Aspergillus fumigatus isolates, and review of azole resistance phenotype and genotype epidemiology in China. [PDF]

Antimicrob Agents Chemother, 2023
Triazole resistance in Aspergillus fumigatus is an increasing worldwide problem that causes major challenges in the management of aspergillosis. New antifungal drugs are needed, with novel targets, that are effective in triazole-resistant infection.
Su H, Zhu M, Tsui CK, van der Lee H, Tehupeiory-Kooreman M, Zoll J, Engel T, Li L, Zhu J, Lu Z, Zhang Q, Verweij PE, Deng S.   +12 more
europepmc   +6 more sources

Pharmacodynamics of the Orotomides against Aspergillus fumigatus: New Opportunities for Treatment of Multidrug-Resistant Fungal Disease [PDF]

mBio, 2017
F901318 is an antifungal agent with a novel mechanism of action and potent activity against Aspergillus spp. An understanding of the pharmacodynamics (PD) of F901318 is required for selection of effective regimens for study in phase II and III clinical ...
William W. Hope, Laura McEntee, Joanne Livermore, Sarah Whalley, Adam Johnson, Nicola Farrington, Ruwanthi Kolamunnage-Dona, Julie Schwartz, Anthony Kennedy, Derek Law, Michael Birch, John H. Rex   +11 more
doaj   +2 more sources

Pharmacodynamics of the Novel Antifungal Agent F901318 for Acute Sinopulmonary Aspergillosis Caused by Aspergillus flavus. [PDF]

J Infect Dis, 2018
Aspergillus flavus is one of the most common agents of invasive aspergillosis and is associated with high mortality. The orotomides are a new class of antifungal agents with a novel mechanism of action. An understanding of the pharmacodynamics (PD) of the lead compound F901318 is required to plan safe and effective regimens for clinical use.The ...
Negri CE, Johnson A, McEntee L, Box H, Whalley S, Schwartz JA, Ramos-Martín V, Livermore J, Kolamunnage-Dona R, Colombo AL, Hope WW.   +10 more
europepmc   +6 more sources